VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
3.3100
-0.1600 (-4.61%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.4700
Open3.4700
Bid3.3600 x 900
Ask3.4300 x 1100
Day's Range3.2202 - 3.4700
52 Week Range1.4400 - 3.5500
Volume104,598
Avg. Volume109,537
Market Cap125.164M
Beta (3Y Monthly)3.00
PE Ratio (TTM)N/A
EPS (TTM)-0.5740
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Trade prices are not sourced from all markets
  • Loss-Making VolitionRx Limited (NYSEMKT:VNRX) Expected To Breakeven
    Simply Wall St.5 days ago

    Loss-Making VolitionRx Limited (NYSEMKT:VNRX) Expected To Breakeven

    VolitionRx Limited's (NYSEMKT:VNRX): VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. On 31 December 2018, the US$128m market-cap pos...

  • PR Newswire15 days ago

    VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. "It has been a busy quarter with the public announcement of a number of initiatives and we were delighted to have the opportunity to discuss our plans at the Capital Markets Day event today," commented Chief Executive Officer, Cameron Reynolds. Following recently announced preliminary results from two proof of concept studies in lung cancer, Volition has signed a Memorandum of Understanding with the prestigious National Taiwan University through its wholly-owned subsidiary, Belgian Volition SPRL ("Belgian Volition"), to conduct a large-scale lung cancer study.

  • PR Newswire15 days ago

    VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.  Any such relationship is subject to the negotiation of terms and conditions and the entry into a final binding agreement.  The MOU contemplates that Belgian Volition would form a new subsidiary in the United States to focus on the veterinary diagnostic market utilizing its NucleosomicsTM technology ("Vetco") and Texas A&M University would collaborate on the research and development of veterinary diagnostic products and is interested in negotiating a shareholding in Vetco.

  • PR Newswire21 days ago

    VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

    ISNES, Belgium, April 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer. Professor Chen Jin-Shing commented: "The early data of the Nu.QTM technology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.

  • PR Newswire27 days ago

    VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

    ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a binding agreement to help facilitate the entrance of the Nu.QTM platform into China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, particularly in lung cancer, subject to reaching agreement on the terms and conditions of the proposed relationship, the parties intend to conduct three clinical studies in China in colorectal cancer, lung cancer and ovarian cancer.

  • PR Newswirelast month

    VolitionRx Limited to Present at Conferences in March & April 2019

    ISNES, Belgium , March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell , is ...

  • Zacks Small Cap Researchlast month

    VNRX: Initial Product Grade Assay Data is Compelling. Strategy Update On April 9th

    VolitionRx (VNRX) reported Q4 financial results and provided a business update. Timelines have been regularly delayed as the clinical grade assays work their way through the ‘product grade’ validation processes and studies.

  • PR Newswirelast month

    VolitionRx Limited to Present at Conferences in the U.S. Next Week

    ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr. Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week. During the conferences, Mr. Reynolds will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced clinical data and upcoming 2019 milestones.

  • PR Newswirelast month

    VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

    ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2018. Volition management will host a conference call tomorrow, March 14, at 8:30a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.

  • PR Newswire2 months ago

    VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update

    Conference call to take place Thursday, March 14, 2019 at 8:30 am Eastern time ISNES, Belgium , March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...

  • Have Insiders Been Buying VolitionRx Limited (NYSEMKT:VNRX) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying VolitionRx Limited (NYSEMKT:VNRX) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...

  • GlobeNewswire5 months ago

    New Research Coverage Highlights Kandi Technologies Group, AquaVenture, Bridgeline Digital, VolitionRX, USD Partners LP, and ZK International Group Co. — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, Nov. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended September 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, November 8, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with good progress being made on many fronts demonstrating the diverse nature of our platform technology.

  • PR Newswire6 months ago

    VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Thursday, November 8, 2018 at 8:30 am Eastern time ISNES, Belgium , Oct. 31, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a ...

  • PR Newswire7 months ago

    VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics

    ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mission at Texas A&M University. The meeting was sponsored in part by the Wallonia Export-Investment Agency (AWEX), a long-time supporter of Volition in Belgium. Volition will now test its Nu.Q™ platform in larger trials in veterinary medicine. Volition's extensive intellectual property portfolio includes coverage of veterinary medicine applications.

  • PR Newswire7 months ago

    VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board

    ISNES, Belgium , Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video ...

  • PR Newswire8 months ago

    VolitionRx Limited to Attend Multiple Conferences in September

    ISNES, Belgium , Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds and/or its Executive Vice President of Investor ...

  • Zacks Small Cap Research8 months ago

    VNRX: More Compelling Prostate Cancer Data, Opportunities Remain for Near-Term Data-Driven Value Inflection

    VolitionRx (VNRX) reported Q2 financial results and provided a business update. Despite the significant operational progress, including that related to their numerous (and growing number of) trials in various cancers, operating spend through the first six months of 2018 was up just $2.4M (+35%) from the prior year period, to $9.2M. For some context of the efficiency of VNRX’s product development, we estimate their average cost per sample (of all ongoing trials) is approximately $100 – a small fraction of the estimated ~$3.5k per sample cost of pivotal studies of other non-invasive CRC diagnostics.

  • ACCESSWIRE8 months ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Volitionrx Limited (NYSE MKT: VNRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...

  • Associated Press8 months ago

    VolitionRX: 2Q Earnings Snapshot

    The Singapore-based company said it had a loss of 15 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.91. A year ago, they were trading at $2.92. _____ This story ...

  • PR Newswire8 months ago

    VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 14, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with strong progress being made on many fronts.

  • PR Newswire8 months ago

    Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. At 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). "This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer.

  • PR Newswire8 months ago

    VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

    ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology for the diagnosis of endometriosis through a simple blood test. Volition has now commenced running its discovery grade assays through the cohorts and expects to report preliminary data over the coming months. Dr. Jake Micallef, Volition's Chief Scientific Officer, commented "Endometriosis is a potentially debilitating inflammatory condition in which the endometrial tissue that normally lines the inside of the uterus, grows outside the uterus, typically damaging the ovaries, fallopian tubes or other tissues of the pelvic cavity.

  • PR Newswire9 months ago

    VolitionRx Announces $9 Million Private Placement

    ISNES, Belgium, Aug. 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a price of $1.80 per share, as well as a warrant to purchase up to an additional 5 million shares of Volition common stock at an exercise price of $3.00 per share payable in cash, which will result in gross proceeds to Volition before the deduction of estimated offering expenses of $9 million (excluding the proceeds from any exercise of the warrant). The warrant will have a term of one year from the closing date and be exercisable for a period of 6 months, commencing on the 6-month anniversary of the closing date. The private placement is expected to close on or about August 10, 2018, subject to customary closing conditions.

  • PR Newswire9 months ago

    VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Tuesday, August 14, 2018 at 8:30 am Eastern time ISNES, Belgium , Aug. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...